Study Reveals BCG Tuberculosis Vaccine May Alter Immune Response Against Alzheimer's
2-minute summary
A recent study published in Communications Medicine demonstrates that the century-old Bacillus Calmette-Guérin (BCG) tuberculosis vaccine can retrain the innate immune system within the central nervous system (CNS). As the human brain ages, it undergoes 'inflammaging'—a state of chronic, low-grade inflammation where immune cells fail to clear toxic amyloid-beta plaques, worsening neurodegeneration in Alzheimer's disease. The study evaluated older adults and discovered that BCG induces 'trained immunity', epigenetically reprogramming monocytes in the cerebrospinal fluid to react more efficiently against non-specific inflammatory threats. In participants without established Alzheimer's disease, BCG vaccination correlated with decreased amyloid levels in cerebrospinal fluid and increased levels in the blood, indicating enhanced clearance of neurotoxic proteins from the brain. However, in individuals with advanced Alzheimer's pathology, the existing severe inflammatory milieu and blood-brain barrier disruption impeded this clearance. Consequently, researchers highlight BCG's potential primarily as an early preventive intervention rather than a curative therapy for advanced dementia.
Why it's in the news
A clinical study from Massachusetts General Hospital has revealed that the BCG vaccine induces trained immunity in the central nervous system, offering a novel preventive strategy against Alzheimer's disease by aiding amyloid-beta clearance.
Background and context
The Bacillus Calmette-Guérin (BCG) vaccine, developed in the early 20th century from an attenuated strain of Mycobacterium bovis, is one of the world's most widely administered vaccines for tuberculosis. Beyond protecting against TB, BCG is known for its heterologous (non-specific) protective effects, including its standard use as an immunotherapy for non-muscle-invasive bladder cancer. Epidemiological studies previously noted that bladder cancer patients receiving BCG therapy exhibited lower rates of dementia. Alzheimer's disease, the leading cause of dementia globally, is characterised by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, accompanied by chronic neuroinflammation. Traditional immunology held that immunological memory was exclusive to the adaptive immune system (B and T lymphocytes). However, recent paradigms recognize 'trained immunity'—a mechanism whereby innate immune cells (like monocytes and macrophages) undergo functional and epigenetic reprogramming to mount heightened responses against unrelated pathogens or pathological stressors.
Constitutional provisions
- Article 47 — Directs the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.
Government schemes
- Universal Immunization Programme (UIP) — Provides free BCG vaccination at birth across India to prevent severe childhood tuberculosis.
- National Programme for Health Care of the Elderly (NPHCE) — Addresses the health and cognitive challenges of the rapidly ageing population in India, including neurodegenerative disorders like dementia.
International organisations
- World Health Organization (WHO) — Leads global action plans on the public health response to dementia and oversees global immunization and tuberculosis monitoring.
Mains practice: What is the concept of 'trained immunity'? Discuss how the repurposing of existing vaccines like BCG opens new frontiers in tackling neurodegenerative diseases and geriatric health issues.
Trained immunity refers to the long-term functional and epigenetic reprogramming of innate immune cells (such as monocytes, macrophages, and natural killer cells), allowing them to mount an enhanced, non-specific immune response against unrelated secondary pathogens or pathological stressors, independent of classical adaptive antibody memory.
Significance in Neurodegenerative Diseases:
• Overcoming 'Inflammaging': Ageing induces chronic, low-grade neuroinflammation that impairs microglial and monocyte clearance of toxic protein aggregates. Trained immunity can restore the responsiveness of central nervous system (CNS) monocytes.
• Enhanced Amyloid Clearance: Repurposed vaccines like BCG have shown potential to mobilize monocytes in the cerebrospinal fluid (CSF), facilitating the transport and clearance of neurotoxic amyloid-beta out of the brain into the systemic circulation.
• Vaccine Repurposing Advantage: Repurposing safe, century-old, and cost-effective vaccines significantly reduces the drug discovery timeline and clinical development costs compared to developing novel monoclonal antibodies.
Implications for Geriatric Healthcare:
• Preventive Strategy: While therapeutic reversal in advanced Alzheimer's remains limited due to blood-brain barrier damage, early-stage vaccination can delay cognitive decline.
• Heterologous Protection: Non-specific immunity offers broad protection against secondary infections, common morbidities among the elderly.
• Scalability in Developing Nations: Low-cost interventions are essential for countries like India facing a surge in dementia cases alongside rapid demographic ageing.
Conclusion:
Trained immunity bridges the gap between innate immune memory and degenerative pathology. Repurposing established immunizations offers a viable, scalable, and preventive paradigm in global and national geriatric public health frameworks.
Prelims practice questions
Q1. With reference to 'Trained Immunity', consider the following statements: 1. It involves the immunological memory of B cells and T cells against specific antigens. 2. It results from epigenetic and metabolic reprogramming of innate immune cells. 3. It allows the immune system to respond more effectively to unrelated pathogens. Which of the statements given above are correct?
- 1 and 2 only
- 2 and 3 only
- 1 and 3 only
- 1, 2 and 3
Answer: B. Statement 1 is incorrect because antigen-specific memory using B and T cells is a feature of adaptive immunity. Trained immunity is a property of the innate immune system (monocytes, macrophages, NK cells) mediated by epigenetic and metabolic changes (Statement 2) enabling broader responsiveness to non-specific, unrelated challenges (Statement 3).
Q2. The Bacillus Calmette-Guérin (BCG) vaccine is widely used for tuberculosis. In non-TB medical practice, it is also standardly approved as an immunotherapy for which of the following conditions?
- Type 1 Diabetes Mellitus
- Non-muscle-invasive Bladder Cancer
- Rheumatoid Arthritis
- Multiple Sclerosis
Answer: B. Intravesical BCG immunotherapy is a standard, well-established treatment to prevent recurrence in non-muscle-invasive bladder cancer.
Q3. Which of the following pathological hallmarks is most commonly associated with Alzheimer's disease?
- Accumulation of extracellular Amyloid-beta plaques
- Dopaminergic neuronal loss in the substantia nigra
- Excessive production of synovial fluid in joint cavities
- Destruction of myelin sheath in the peripheral nervous system
Answer: A. Alzheimer's disease is primarily characterized by the accumulation of extracellular amyloid-beta plaques and intracellular hyperphosphorylated tau neurofibrillary tangles in the brain. Dopaminergic neuronal loss is characteristic of Parkinson's disease, and demyelination in the PNS is seen in disorders like Guillain-Barré syndrome.
Revision flashcards
- What is 'Trained Immunity'? The process by which innate immune cells (e.g., monocytes, macrophages) undergo epigenetic and metabolic reprogramming to build non-specific memory against diverse, unrelated threats.
- What is 'Inflammaging'? A chronic, sterile, low-grade systemic inflammation that develops during natural ageing, impairing normal immune functions and driving neurodegenerative diseases.
- What is the BCG vaccine composed of? A live-attenuated strain of Mycobacterium bovis, originally developed to prevent tuberculosis.
- How does BCG vaccination impact amyloid-beta in pre-symptomatic Alzheimer's models? It stimulates innate immune cells to facilitate the clearance of amyloid-beta from the cerebrospinal fluid into peripheral circulation.
- Why is BCG less effective in established Alzheimer's disease? The severely inflamed brain environment, dense plaques, and damaged blood-brain barrier overwhelm and hinder retrained immune cells.